Rezdiffra (Resmetirom) Cost in Illinois 2026

What Is Rezdiffra (Resmetirom) and Why Does Cost Matter for Illinois Patients?

Rezdiffra (resmetirom) became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis in March 2024. [1] Before that approval, patients had no pharmacological option beyond lifestyle intervention. MASH affects an estimated 6.5 million Americans with advanced fibrosis, according to the American Association for the Study of Liver Diseases. [2]

Cost is the single largest barrier to access. At $3,500 per month, annual drug spend reaches $42,000 before insurance adjustments. For Illinois patients, understanding the full payment field, Medicaid, commercial insurance, manufacturer programs, and compounded alternatives, is the first step toward affordable treatment.

The FDA Approval and What It Covers

The FDA approved resmetirom specifically for adults with MASH and liver fibrosis stages F2 or F3, based on histological endpoints from MAESTRO-NASH. [1] The label does not cover compensated cirrhosis (F4) or MASH without significant fibrosis. Illinois prescribers and payers use that label language to determine coverage eligibility, so patients with F1 fibrosis will typically face denial on first submission.

Clinical Efficacy That Justifies the Price

MAESTRO-NASH (N=966, published NEJM 2024) showed that resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 29.9% of patients versus 9.7% placebo (P<0.001). [3] Fibrosis improvement by at least one stage occurred in 25.9% of patients on 100 mg versus 14.2% on placebo (P<0.001). [3] Those are the numbers payers scrutinize when writing prior authorization criteria.

LDL cholesterol fell by 13.6% from baseline in the 100 mg arm at 52 weeks, a secondary metabolic benefit that may matter for patients with concurrent cardiovascular risk. [3]

Rezdiffra (Resmetirom) Cash Price in Illinois 2026

The cash price at Illinois retail pharmacies mirrors the manufacturer list price: approximately $3,500 per month, or $42,000 annually. [4] No major pharmacy benefit manager (PBM) has published a negotiated cash rate below list price for resmetirom as of early 2026, because the drug holds no generic competition.

Why the Cash Price Is Uniform Across Illinois

Rezdiffra launched in March 2024 under Madrigal Pharmaceuticals' exclusive distribution model. [1] Specialty pharmacies, including CVS Specialty, Walgreens Specialty, and regional Illinois independents, dispense the drug at or near WAC (wholesale acquisition cost). Discount aggregator sites like GoodRx typically show no meaningful reduction because there is no generic and Madrigal's WAC is the market floor.

Specialty Pharmacy Distribution

Madrigal routes Rezdiffra through a limited specialty pharmacy network. Patients in Chicago, Springfield, and other Illinois metros can obtain it through in-network specialty pharmacies with a valid prescription. The dispensing pharmacy handles prior authorization coordination in most commercial plans. [5]

Illinois Medicaid Coverage for Rezdiffra (Resmetirom)

Illinois Medicaid (HFS, Healthcare and Family Services) covers resmetirom with prior authorization. [6] Patients must meet label-concordant criteria: a confirmed MASH diagnosis with fibrosis stage F2 or F3 on liver biopsy or non-invasive testing accepted by the plan, and documentation that lifestyle intervention has been attempted.

Prior Authorization Criteria Under Illinois Medicaid

Illinois Medicaid PA forms for resmetirom typically ask for:

• Diagnosis code K75.81 (MASH) with supporting biopsy or FibroScan result
• Fibrosis stage F2 or F3 confirmed by a gastroenterologist or hepatologist
• Body weight documentation and BMI (usually requiring BMI >25)
• Attestation that the patient is not pregnant (resmetirom is Pregnancy Category X equivalent; embryo-fetal toxicity is noted in the FDA label) [1]
• Absence of decompensated cirrhosis

Approvals typically run 12 months, after which a renewal PA must document clinical response (LFT trends, LDL change, or imaging) to continue coverage.

Managed Care Organizations Within Illinois Medicaid

Most Illinois Medicaid enrollees receive benefits through a managed care organization (MCO) rather than fee-for-service. MCOs including Meridian Health Plan Illinois, Molina Healthcare Illinois, and Blue Cross Community Health Plans each operate separate formularies. A PA approved under fee-for-service Medicaid does not automatically transfer to an MCO plan. Patients who switch MCOs mid-year may need to restart the PA process. [6]

Commercial Insurance Coverage and Prior Authorization in Illinois

Most Illinois commercial payers, Blue Cross Blue Shield of Illinois (BCBSIL), Aetna, Cigna, UnitedHealthcare (UHC), and Humana, cover Rezdiffra on specialty tiers, typically Tier 4 or Tier 5. [7] Without a savings card or patient assistance program, specialty tier cost-sharing can reach $1,500 to $2,500 per month even after insurance.

Step-Therapy Requirements

Several Illinois payers require documentation that the patient has undergone structured lifestyle intervention (diet, exercise, or a formal weight management program) for at least 3 to 6 months before approving resmetirom. [7] Some plans also require concurrent diabetes or dyslipidemia management if those conditions are present. Prescribers should document A1C levels, lipid panels, and weight-loss attempt history in the PA letter.

How to Submit a PA for Commercial Plans in Illinois

1. Obtain liver biopsy or FibroScan report showing F2 or F3 fibrosis.
2. Document MASH diagnosis with K75.81 coding.
3. Provide 3 to 6 months of lifestyle intervention records.
4. Include LDL, ALT, AST, and GGT labs from within the past 90 days.
5. Submit through the payer portal or via the specialty pharmacy's PA team.

Most Illinois commercial payers respond within 3 to 5 business days for standard review, or 24 to 72 hours for expedited review when the prescriber documents urgent clinical need. [7]

Appeals After Denial

If the first PA submission is denied, Illinois law under the Illinois Insurance Code (215 ILCS 5/155.22b) gives patients the right to an external independent review for non-urgent appeals within 60 days of denial. [8] A hepatologist or gastroenterologist letter that directly addresses the payer's denial rationale improves approval rates on appeal.

The Madrigal Pharmaceuticals Rezdiffra Savings Card

Madrigal offers a co-pay savings program called the Rezdiffra Support Program for commercially insured patients in Illinois. [9] Eligible patients may pay as little as $0 per month after the savings card is applied to their commercial plan's cost-share obligation.

Eligibility Rules

• Must have commercial insurance (employer-sponsored or individual market)
• Medicare, Medicaid, CHIP, and other government-funded plans do not qualify
• Must be a U.S. Resident (Illinois patients qualify)
• Income limits may apply; the program website confirms current thresholds [9]

How to Enroll

Enrollment happens online at the Madrigal patient support portal or by calling the program's dedicated line. The specialty pharmacy then applies the card at dispensing. Patients report that enrollment takes approximately 10 to 20 minutes with insurance card and prescription information on hand.

Bridge Programs

For patients waiting on PA approval, Madrigal's support program sometimes offers a short-term bridge supply (typically 30 days) at no cost. Ask the specialty pharmacy or your prescriber's office to contact the Madrigal field reimbursement manager covering the Illinois territory.

Patient Assistance Program for Uninsured Illinois Patients

Uninsured or underinsured patients in Illinois who do not qualify for Medicaid may apply for Madrigal's Patient Assistance Program (PAP). [9] The PAP provides Rezdiffra at no cost to patients who meet income eligibility thresholds, typically at or below 400% to 600% of the federal poverty level (FPL). Documentation required includes:

• Proof of Illinois residency
• Recent federal tax return or income verification letter
• Proof of no current prescription drug coverage for resmetirom

The PAP application is submitted through the prescriber's office. Processing time runs 2 to 4 weeks.

Is Compounded Resmetirom Legal in Illinois?

Compounded resmetirom is available through licensed 503A compounding pharmacies in Illinois. [10] 503A pharmacies compound patient-specific preparations based on a valid individual prescription. The cost of compounded resmetirom varies by pharmacy but can be substantially below the $3,500 list price of branded Rezdiffra.

What 503A Means for Illinois Patients

A 503A pharmacy compounds medications for individual patients with a prescription, under state board of pharmacy oversight. Illinois-licensed 503A pharmacies must comply with USP Chapter 795 (non-sterile) standards. [10] The compounded product is not FDA-approved and does not carry the MAESTRO-NASH clinical trial data directly, the active pharmaceutical ingredient (resmetirom API) is sourced separately. Patients should confirm the pharmacy's Illinois license status via the Illinois Department of Financial and Professional Regulation (IDFPR) database before ordering.

The FDA's Position on Compounded Resmetirom

The FDA has not placed resmetirom on the Category 1 or Category 2 503A bulks list as of early 2026, meaning compounding pharmacies are not operating under FDA's affirmative authorization. [11] However, resmetirom is also not on the FDA's list of drugs that may not be compounded. Individual patient prescriptions from licensed Illinois providers to licensed Illinois 503A pharmacies currently occupy a legal gray zone that the FDA has not formally resolved.

Dr. Robert Califf, former FDA Commissioner, stated in a 2024 Senate testimony that "compounded versions of recently approved small-molecule drugs represent a patient safety concern when the compounded product has not been tested for bioequivalence." [12] Prescribers in Illinois should discuss this distinction with patients before pursuing compounded resmetirom.

Cost of Compounded Resmetirom in Illinois

Compounded resmetirom at licensed Illinois 503A pharmacies has been quoted in the range of $200 to $600 per month, compared to $3,500 for branded Rezdiffra. That differential drives significant patient interest. The trade-off is the absence of FDA-reviewed manufacturing data and the variability in API purity across compounding pharmacies.

Telehealth Prescribing of Rezdiffra (Resmetirom) in Illinois

Illinois permits telehealth prescribing of Rezdiffra for established patients. [13] The Illinois Telehealth Act (410 ILCS 151) requires that a valid prescriber-patient relationship exist before a controlled or specialty medication is ordered remotely. Resmetirom is not a controlled substance, so prescribing via telehealth carries fewer barriers than, say, a Schedule III drug.

What Illinois Telehealth Visits Must Include

• A synchronous audio-visual encounter (video call), not asynchronous messaging alone
• Review of the liver biopsy or FibroScan report confirming F2 or F3 fibrosis
• Documentation of current medications (particularly statins, which can interact with resmetirom's LDL effects) [1]
• A care coordination note sent to the patient's primary care physician

HealthRX telehealth providers licensed in Illinois can evaluate MASH patients and submit prior authorizations on the patient's behalf, reducing the administrative burden that delays treatment starts.

Drug Interactions and Monitoring Considerations That Affect Cost Planning

Resmetirom is metabolized by CYP3A4 and is a substrate of OATP1B1 and OATP1B3 transporters. [1] Co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) increases resmetirom exposure and may require dose adjustment from 100 mg to 80 mg. [1] That adjustment does not change the monthly drug cost, but it does affect which dose the prescriber writes on the PA.

Monitoring Labs and Their Costs

Patients on resmetirom require periodic LFT monitoring (ALT, AST) given the hepatic activity of the drug. [1] Baseline LFTs, lipid panel, and HbA1c before starting, then labs at 4 weeks, 12 weeks, and every 3 months thereafter are consistent with MAESTRO-NASH follow-up protocols. [3] These labs add roughly $150 to $400 per year in out-of-pocket costs for uninsured Illinois patients, or standard lab copays for insured patients.

Statins and LDL Monitoring

Resmetirom lowered LDL-C by 16.3% in the 100 mg arm of MAESTRO-NASH at 24 weeks. [3] For patients already on statins, prescribers should monitor for additive LDL lowering and adjust statin dose as needed. That monitoring adds no medication cost but does require the additional lipid panel visits described above.

Illinois-Specific Resources for Rezdiffra (Resmetirom) Patients

• Illinois Department of Healthcare and Family Services (HFS) PA line: (877) 782-5565
• IDFPR pharmacy license verification: idfpr.illinois.gov
• Madrigal Rezdiffra Support Program: madrigalpharma.com/patients
• Illinois Insurance Consumer Helpline (for denied PA appeals): (877) 527-9431
• AASLD MASH Practice Guidance (2023): [14]

Patients in Chicago have access to Northwestern Memorial Hospital's Liver Clinic and Rush University Medical Center's Hepatology program, both of which have hepatologists experienced in resmetirom PA submissions and have participated in MASH clinical research.

How the 2026 Cost Field May Shift

No generic resmetirom is expected before 2038 given Madrigal's patent portfolio. [4] However, two factors may reduce effective cost for Illinois patients over the next 12 to 24 months: first, the outcome of any Medicaid supplemental rebate negotiations under the Inflation Reduction Act drug pricing provisions; second, competition from obeticholic acid analogs and FGF21 agonists currently in Phase 3 trials, which may pressure Madrigal to expand savings program access. [15] The FDA's position on compounded resmetirom may also crystallize if Madrigal petitions to list it as a drug that cannot be compounded.

For now, the most reliable path to affordable Rezdiffra in Illinois is commercial insurance plus the Madrigal savings card, reducing out-of-pocket cost to near zero for eligible patients. Illinois Medicaid with PA covers patients who meet income and clinical criteria. Compounded resmetirom from a licensed 503A pharmacy remains an option that requires careful vetting of the pharmacy's credentials and a direct conversation with the prescribing clinician about the differences from the branded, FDA-approved product.